Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05399537 · ClinicalTrials.gov registry record · Phase 3

Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

A Phase 3 study of Acute Kidney Injury (AKI) and Regional Citrate Anticoagulation (RCA), sponsored by Vantive Health.

Recruiting
Registry status
Phase 3
Development phase
40
Enrollment target
14
Study locations

NCT05399537 is a Phase 3 study of Acute Kidney Injury (AKI) and Regional Citrate Anticoagulation (RCA) that is actively recruiting participants, run by Vantive Health. The registered enrollment target is 40 participants, below the 4,628-participant average among 4 other Acute Kidney Injury (AKI) trials with a reported enrollment target (99% lower). The trial reports 14 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05399537, a Phase 3 study of Acute Kidney Injury (AKI) and Regional Citrate Anticoagulation (RCA), is actively recruiting participants, sponsored by Vantive Health.

RECRUITING
Registry status
Phase 3
Development phase
40 participants
Enrollment target
14
Study locations

Study Summary

Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate anticoagulation (RCA) software to facilitate citrate and calcium compensation prescription. The objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription. The study period of the patient's CRRT will be up to 10 days.

Conditions Studied

Acute Kidney Injury (AKI) Regional Citrate Anticoagulation (RCA) Continuous Renal Replacement Therapy (CRRT)

Interventions

  • DRUG Prismocitrate 18
  • DEVICE PrisMax System Version 3.x with calcium line accessory

Study Locations (14)

Pennsylvania

  • Geisinger Medical Center - Danville
  • Penn State Hershey Medical Center - Hershey
  • VA Pittsburgh Healthcare System - Pittsburgh

California

  • University of Southern California (USC) / Keck Hospital - Los Angeles
  • University of California Los Angeles - Los Angeles

Texas

  • Methodist Dallas Medical Center - Dallas
  • Gamma Medical Research, Inc / McAllen Medical Center - McAllen

Alabama

  • University of Alabama at Birmingham/UAB - Birmingham

Florida

  • University of Miami - Miami

Georgia

  • Emory University - Atlanta

Michigan

  • University of Michigan - Ann Arbor

Ohio

  • Bon Secours Mercy Health-Springfield Regional Medical Center - Springfield

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-07-12
Est. Completion 2026-12
Phase Phase 3

Sponsor

Vantive Health

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05399537

The ClinicalTrials.gov registry entry for NCT05399537 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,628-participant average among 4 other Acute Kidney Injury (AKI) trials with a reported enrollment target (99% lower). The listed sponsor is Vantive Health, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Kidney Injury (AKI) appearing as the primary indexed condition, and to 2 interventions - of which Prismocitrate 18 is the first listed.

NCT05399537 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Pennsylvania, California, Texas.

Frequently Asked Questions

What is clinical trial NCT05399537 about?

NCT05399537 is a clinical study titled "Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT". Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate antico...

What is the current status of trial NCT05399537?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2024-07-12. Estimated completion is 2026-12.

What conditions does trial NCT05399537 study?

This clinical trial studies the following conditions: Acute Kidney Injury (AKI), Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT).

What interventions are being tested in trial NCT05399537?

The interventions under investigation include: Prismocitrate 18 (DRUG), PrisMax System Version 3.x with calcium line accessory (DEVICE).

Who is sponsoring clinical trial NCT05399537?

This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05399537 being conducted?

This trial has 14 study locations across Alabama, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Kidney Injury (AKI)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Kidney Injury (AKI)

All registered trials for this condition

Regional Citrate Anticoagulation (RCA)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.